Cite
The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb trial.
MLA
Worm, Margitta, et al. “The Pan‐JAK Inhibitor Delgocitinib in a Cream Formulation Demonstrates Dose Response in Chronic Hand Eczema in a 16‐week Randomized Phase IIb Trial.” British Journal of Dermatology, vol. 187, no. 1, July 2022, pp. 42–51. EBSCOhost, https://doi.org/10.1111/bjd.21037.
APA
Worm, M., Thyssen, J. P., Schliemann, S., Bauer, A., Shi, V. Y., Ehst, B., Tillmann, S., Korn, S., Resen, K., & Agner, T. (2022). The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb trial. British Journal of Dermatology, 187(1), 42–51. https://doi.org/10.1111/bjd.21037
Chicago
Worm, Margitta, Jacob P. Thyssen, Sibylle Schliemann, Andrea Bauer, Vivian Y. Shi, Ben Ehst, Sandra Tillmann, Sofie Korn, Katarina Resen, and Tove Agner. 2022. “The Pan‐JAK Inhibitor Delgocitinib in a Cream Formulation Demonstrates Dose Response in Chronic Hand Eczema in a 16‐week Randomized Phase IIb Trial.” British Journal of Dermatology 187 (1): 42–51. doi:10.1111/bjd.21037.